MME and angioedema: The neprilysin inhibitor, omapatrilat, which is actually a combined inhibitor of angiotensin-converting enzyme and neprilysin, showed promising results in HFrEF, but further investigation of this compound was hindered by excessive angioedema in a subsequent phase III clinical trial [48, 49].